{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:00:09Z","timestamp":1790830809303,"version":"4.1.0"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>To explore the clinical characteristics of atezolizumab-associated encephalitis and to provide clinical evidence for diagnosis and treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Clinical reports on atezolizumab-associated encephalitis published before June 30, 2026 were collected for retrospective analysis by searching Chinese and English databases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 39 cases of encephalitis were included, with a median age of 60 years (33, 78). The median time of symptom onset was 14 days (2, 420) after the initial administration. Fever (53.8%), confusion (51.3%) and headache (28.2%) were the main complaints of the patients. Cerebrospinal fluid examination showed elevated white blood cell count and protein, with median values of 27 cells\/\u03bcL (1, 553) and 133mg\/dL (27.1, 815), respectively. Brain magnetic resonance imaging showed T2 fluid-attenuated inversion recovery hyperintensities in half of the patients. Electroencephalogram showed display epileptiform discharges (26.7%) and slow waves (40.0%). After discontinuation of atezolizumab and initiation of targeted treatment, 97.4% of patients achieved symptomatic improvement or recovery, while 2.6% died of encephalitis-related complications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Patients with atezolizumab-associated encephalitis were predominantly middle-aged and elderly, with fever, confusion and headache as the major manifestations. Clinicians should be alert to the potential risk of encephalitis during atezolizumab treatment. Most patients obtained symptom relief or clinical recovery following atezolizumab discontinuation and treatment; only a few succumbed to severe encephalitis-related complications.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1943615","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T04:43:09Z","timestamp":1790829789000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical features and outcomes of atezolizumab-associated encephalitis"],"prefix":"10.3389","volume":"17","author":[{"given":"Chunjiang","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The Third Xiangya Hospital, Central South University","place":["Changsha, Hunan, China"]},{"name":"College of Pharmacy, Changsha Medical University","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Third Xiangya Hospital, Central South University","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The Third Xiangya Hospital, Central South University","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoli","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, The Third Xiangya Hospital, Central South University","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-016-0618-8","article-title":"Atezolizumab: First global approval","volume":"76","author":"Markham","year":"2016","journal-title":"Drugs"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01398-6","article-title":"Atezolizumab: A review in extensive-stage SCLC","volume":"80","author":"Frampton","year":"2020","journal-title":"Drugs"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): A phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.06.007","article-title":"Updated overall survival by circulating tumor DNA status from the phase 3 IMvigor010 trial: Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma","volume":"85","author":"Powles","year":"2024","journal-title":"Eur Urol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02098-5","article-title":"Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): A randomised, multicentre, open-label, phase 3 trial","volume":"398","author":"Felip","year":"2021","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2507874","article-title":"Atezolizumab plus FOLFOX for stage III mismatch repair-deficient colon cancer","volume":"394","author":"Sinicrope","year":"2026","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/antib13030056","article-title":"Immune-related adverse events associated with atezolizumab: Insights from real-world pharmacovigilance data","volume":"13","author":"Frey","year":"2024","journal-title":"Antibodies (Basel)"},{"key":"B8","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S1474-4422(15)00401-9","article-title":"A clinical approach to diagnosis of autoimmune encephalitis","volume":"15","author":"Graus","year":"2016","journal-title":"Lancet Neurol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s40425-019-0617-x","article-title":"Neurologic toxicity associated with immune checkpoint inhibitors: A pharmacovigilance study","volume":"7","author":"Johnson","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0487","article-title":"Neurologic serious adverse events associated with nivolumab plus ipilimumab or nivolumab alone in advanced melanoma, including a case series of encephalitis","volume":"22","author":"Larkin","year":"2017","journal-title":"Oncologist"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s43441-021-00365-x","article-title":"The occurrence of encephalitis due to immune checkpoint inhibitors: A pharmacovigilance study","volume":"56","author":"Chisaki","year":"2022","journal-title":"Ther Innov Regul Sci"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-01569","article-title":"Chemoradiation \u00b1 atezolizumab in limited-stage small cell lung cancer: Results of NRG Oncology\/Alliance LU005","volume":"44","author":"Higgins","year":"2026","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-022-01395-7","article-title":"Sex differences in immune-related adverse events with immune checkpoint inhibitors: Data mining of the FDA adverse event reporting system","volume":"44","author":"Chen","year":"2022","journal-title":"Int J Clin Pharm"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200314","article-title":"Clinical course of neurologic adverse events associated with immune checkpoint inhibitors: Focus on chronic toxicities","volume":"11","author":"Rossi","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B15","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1053\/j.seminoncol.2018.08.006","article-title":"Aging, immune senescence, and immunotherapy: A comprehensive review","volume":"45","author":"Elias","year":"2018","journal-title":"Semin Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2010.224105","article-title":"Which antibody and which cancer in which paraneoplastic syndromes","volume":"10","author":"Gozzard","year":"2010","journal-title":"Pract Neurol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-013-7234-2","article-title":"The presence of oligoclonal IgG bands in human CSF during the course of neurological diseases","volume":"261","author":"Haertle","year":"2014","journal-title":"J Neurol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.4065\/mcp.2010.0099","article-title":"Paraneoplastic syndromes: An approach to diagnosis and treatment","volume":"85","author":"Pelosof","year":"2010","journal-title":"Mayo Clin Proc"},{"key":"B19","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1200\/JCO.2004.01.028","article-title":"Hu and voltage-gated calcium channel (VGCC) antibodies related to the prognosis of small-cell lung cancer","volume":"22","author":"Monstad","year":"2004","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2017.144","article-title":"Inflammatory CNS disease caused by immune checkpoint inhibitors: Status and perspectives","volume":"13","author":"Yshii","year":"2017","journal-title":"Nat Rev Neurol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00141-6","article-title":"Innate and adaptive immune responses in the CNS","volume":"14","author":"Waisman","year":"2015","journal-title":"Lancet Neurol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"5555","DOI":"10.1038\/s41467-023-40982-8","article-title":"PD-L1 positive astrocytes attenuate inflammatory functions of PD-1 positive microglia in models of autoimmune neuroinflammation","volume":"14","author":"Linnerbauer","year":"2023","journal-title":"Nat Commun"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51213","article-title":"HLA-B27 association of autoimmune encephalitis induced by PD-L1 inhibitor","volume":"7","author":"Chang","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.0057","article-title":"NCCN Guidelines\u00ae Insights: Management of immunotherapy-related toxicities, Version 2.2024","volume":"22","author":"Thompson","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.1022","article-title":"Evaluation of readministration of immune checkpoint inhibitors after immune-related adverse events in patients with cancer","volume":"5","author":"Simonaggio","year":"2019","journal-title":"JAMA Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0755","article-title":"Safety and efficacy of re-treating with immunotherapy after immune-related adverse events in patients with NSCLC","volume":"6","author":"Santini","year":"2018","journal-title":"Cancer Immunol Res"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1943615\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T04:43:12Z","timestamp":1790829792000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1943615\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":28,"alternative-id":["10.3389\/fimmu.2026.1943615"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1943615","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]},"article-number":"1943615"}}